![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Non inferiority of dolutegravir+emtricitabine dual therapy
to standard combination antiretroviral therapy
in maintaining HIV suppression throughout 48 weeks:
The SIMPL'HIV study
|
|
|
17th European AIDS Conference, November 6-9, 2019, Basel
Reported by Jules Levin
![First](../images/111219/111219-2/First)
![1112191](../images/111219/111219-2/1112191.gif)
![1112192](../images/111219/111219-2/1112192.gif)
![1112193](../images/111219/111219-2/1112193.gif)
![1112194](../images/111219/111219-2/1112194.gif)
![1112195](../images/111219/111219-2/1112195.gif)
![1112196](../images/111219/111219-2/1112196.gif)
![1112197](../images/111219/111219-2/1112197.gif)
![1112198](../images/111219/111219-2/1112198.gif)
![1112199](../images/111219/111219-2/1112199.gif)
![11121910](../images/111219/111219-2/11121910.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|